Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)

Phase I/II Trial of Weekly Docetaxel and Cisplatin for Locoregional Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Study Objectives:

• To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
• To determine the response rate of the recommended dose
• To determine the safety and tolerability of the recommended dose

Study Overview

• Status: Completed
• Conditions: Head and Neck Neoplasms
• Intervention / Treatment: Drug: Docetaxel

• Study Type: Interventional
• Enrollment: 45
• Phase: Phase 2; Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically confirmed (of original primary tumor) locoregional recurrent and/or metastatic following prior radiotherapy and/or surgery and not amenable to further curative local therapy for SCCHN
• Measurable disease as defined by at least the longest diameter measured as 20 mm by conventional CT or 10 mm by spiral CT. Physical measurements are allowed if longest diameter is 20 mm by caliper measurements.
• ECOG performance status 0-2

• Adequate bone marrow and hepatic function as evidenced by the following:

  • Hematology (Bone marrow):

    • Neutrophils ≥ 1.50 x 10^9/L
    • Platelets ≥ 100 x 10^9/L
    • Hemoglobin ≥ 10 g/dL

  • Hepatic function:

    • AST and/or ALT: < 2X ULN (Upper Limit of Normal)
    • Bilirubin < 1X ULN
• Adequate renal function with calculated or measured glomerular filtration rate of > 60 ml/min calculated by the Cockcroft- Gault method

• No severe intercurrent illness or other serious illness or medical conditions including but not limited to:

  • Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry.
  • Active uncontrolled infection
  • Active peptic ulcer
  • Chronic obstructive pulmonary disease requiring hospitalization during the year preceding study entry
• No prior chemotherapy for recurrent/advanced SCCHN with platinum or taxane regimen (primary radiosensitizing platinum allowed).
• No other diagnosed malignancy other than basal cell carcinoma of the skin or cervix carcinoma in situ

Exclusion Criteria:

• Prior therapy with taxanes either adjuvant, neoadjuvant, concurrent or in advanced stage disease
• Prior chemotherapy for locoregional recurrent/metastatic SCCHN with palliative intent

• Contraindications from

  • the medical history (i.e. known hepatitis, HIV) and physical exam
  • laboratory tests (hematology, biochemistry)
  • 12-lead electrocardiogram
  • blood pressure and pulse
• Pregnancy
• Breast-feeding
• Treatment with any investigational product in the last 4 weeks before study entry
• Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
• Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
• History of hypersensitivity to the study drug(s) or to drugs with a similar chemical structure
• Impaired hepatic function, as shown by bilirubin greater than upper limits of normal and/or AST greater than 2 times upper limits of normal
• Impaired renal function, as shown by measured or calculated creatinine clearance of < 60 ml/min or absolute creatinine level > 1.5 upper limit of normal

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
AE SAE collection	from the inform consent signed up to the end of the study

Collaborators and Investigators

• Sponsor: Sanofi
• Investigators: Study Director: Monique Furlan, Sanofi

Study record dates

Study Major Dates

• Study Start: August 1, 2003
• Primary Completion (Actual): April 1, 2006
• Study Completion: April 1, 2006

Study Registration Dates

• First Submitted: December 21, 2005
• First Submitted That Met QC Criteria: December 21, 2005
• First Posted (Estimate): December 22, 2005

Study Record Updates

• Last Update Posted (Estimate): December 7, 2009
• Last Update Submitted That Met QC Criteria: December 4, 2009
• Last Verified: December 1, 2009

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Squamous Cell; Head and Neck Neoplasms; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Docetaxel
• Other Study ID Numbers: XRP6976G_2501

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No